229 related articles for article (PubMed ID: 38030626)
41. The p53-binding protein 1-Tudor-interacting repair regulator complex participates in the DNA damage response.
Zhang A; Peng B; Huang P; Chen J; Gong Z
J Biol Chem; 2017 Apr; 292(16):6461-6467. PubMed ID: 28213517
[TBL] [Abstract][Full Text] [Related]
42. A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein.
Bhat DS; Spies MA; Spies M
DNA Repair (Amst); 2022 Dec; 120():103421. PubMed ID: 36327799
[TBL] [Abstract][Full Text] [Related]
43. Functional crosstalk between DNA damage response proteins 53BP1 and BRCA1 regulates double strand break repair choice.
Bakr A; Köcher S; Volquardsen J; Reimer R; Borgmann K; Dikomey E; Rothkamm K; Mansour WY
Radiother Oncol; 2016 May; 119(2):276-81. PubMed ID: 26615718
[TBL] [Abstract][Full Text] [Related]
44. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.
Nakada S; Yonamine RM; Matsuo K
Cancer Res; 2012 Oct; 72(19):4974-83. PubMed ID: 22865450
[TBL] [Abstract][Full Text] [Related]
45. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
Bouwman P; Aly A; Escandell JM; Pieterse M; Bartkova J; van der Gulden H; Hiddingh S; Thanasoula M; Kulkarni A; Yang Q; Haffty BG; Tommiska J; Blomqvist C; Drapkin R; Adams DJ; Nevanlinna H; Bartek J; Tarsounas M; Ganesan S; Jonkers J
Nat Struct Mol Biol; 2010 Jun; 17(6):688-95. PubMed ID: 20453858
[TBL] [Abstract][Full Text] [Related]
46. REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
Taglialatela A; Leuzzi G; Sannino V; Cuella-Martin R; Huang JW; Wu-Baer F; Baer R; Costanzo V; Ciccia A
Mol Cell; 2021 Oct; 81(19):4008-4025.e7. PubMed ID: 34508659
[TBL] [Abstract][Full Text] [Related]
47. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Patel PS; Algouneh A; Hakem R
Oncogene; 2021 Apr; 40(17):3001-3014. PubMed ID: 33716297
[TBL] [Abstract][Full Text] [Related]
48. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract][Full Text] [Related]
49. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
Hamid AB; Frank LE; Bouley RA; Petreaca RC
PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
[TBL] [Abstract][Full Text] [Related]
50. EXO1 protects BRCA1-deficient cells against toxic DNA lesions.
van de Kooij B; Schreuder A; Pavani R; Garzero V; Uruci S; Wendel TJ; van Hoeck A; San Martin Alonso M; Everts M; Koerse D; Callen E; Boom J; Mei H; Cuppen E; Luijsterburg MS; van Vugt MATM; Nussenzweig A; van Attikum H; Noordermeer SM
Mol Cell; 2024 Feb; 84(4):659-674.e7. PubMed ID: 38266640
[TBL] [Abstract][Full Text] [Related]
51. Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity.
Syed A; Filandr F; Patterson-Fortin J; Bacolla A; Ravindranathan R; Zhou J; McDonald DT; Albuhluli ME; Verway-Cohen A; Newman JA; Tsai MS; Jones DE; Schriemer DC; D'Andrea AD; Tainer JA
Nucleic Acids Res; 2023 Oct; 51(18):9920-9937. PubMed ID: 37665033
[TBL] [Abstract][Full Text] [Related]
52. Regulation of DNA repair in the absence of classical non-homologous end joining.
Kang YJ; Yan CT
DNA Repair (Amst); 2018 Aug; 68():34-40. PubMed ID: 29929045
[TBL] [Abstract][Full Text] [Related]
53. Super-resolution mapping of cellular double-strand break resection complexes during homologous recombination.
Whelan DR; Rothenberg E
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33707212
[TBL] [Abstract][Full Text] [Related]
54. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Tacconi EM; Lai X; Folio C; Porru M; Zonderland G; Badie S; Michl J; Sechi I; Rogier M; Matía García V; Batra AS; Rueda OM; Bouwman P; Jonkers J; Ryan A; Reina-San-Martin B; Hui J; Tang N; Bruna A; Biroccio A; Tarsounas M
EMBO Mol Med; 2017 Oct; 9(10):1398-1414. PubMed ID: 28729482
[TBL] [Abstract][Full Text] [Related]
55. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
56. Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.
Schrempf A; Slyskova J; Loizou JI
Trends Cancer; 2021 Feb; 7(2):98-111. PubMed ID: 33109489
[TBL] [Abstract][Full Text] [Related]
57. Targeting Polymerase Theta (POLθ) for Cancer Therapy.
Patterson-Fortin J; D'Andrea AD
Cancer Treat Res; 2023; 186():285-298. PubMed ID: 37978141
[TBL] [Abstract][Full Text] [Related]
58. Role of 53BP1 in end protection and DNA synthesis at DNA breaks.
Paiano J; Zolnerowich N; Wu W; Pavani R; Wang C; Li H; Zheng L; Shen B; Sleckman BP; Chen BR; Nussenzweig A
Genes Dev; 2021 Oct; 35(19-20):1356-1367. PubMed ID: 34503990
[TBL] [Abstract][Full Text] [Related]
59. Mitotic regulators TPX2 and Aurora A protect DNA forks during replication stress by counteracting 53BP1 function.
Byrum AK; Carvajal-Maldonado D; Mudge MC; Valle-Garcia D; Majid MC; Patel R; Sowa ME; Gygi SP; Harper JW; Shi Y; Vindigni A; Mosammaparast N
J Cell Biol; 2019 Feb; 218(2):422-432. PubMed ID: 30602538
[TBL] [Abstract][Full Text] [Related]
60. H4K20me2 distinguishes pre-replicative from post-replicative chromatin to appropriately direct DNA repair pathway choice by 53BP1-RIF1-MAD2L2.
Simonetta M; de Krijger I; Serrat J; Moatti N; Fortunato D; Hoekman L; Bleijerveld OB; Altelaar AFM; Jacobs JJL
Cell Cycle; 2018; 17(1):124-136. PubMed ID: 29160738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
